Group 1 - The Hong Kong Stock Connect Innovative Drug ETF (Southern, 159297) has seen a rise of 1.48% as of January 14, 2026, with a turnover of 2.21% and a transaction volume of 37.37 million yuan [1] - The ETF's latest scale reached 1.671 billion yuan and the latest share count reached 1.883 billion, both hitting record highs since its inception [1] - The 44th JPMorgan Healthcare Conference is being held from January 12 to 15, 2026, in San Francisco, focusing on biotechnology, biopharmaceuticals, and AI in medicine, marking it as a significant investment and trading window for the global pharmaceutical industry [1] Group 2 - Yilian Biotech announced a new exclusive licensing agreement with Roche for the YL201 project, which includes an upfront payment of $570 million and potential milestone payments [2] - Haizhi Science signed a licensing agreement with AirNexis for the HSK39004 project, with a total transaction value exceeding $1 billion, currently in Phase II clinical trials in China [2] - Zhongsheng Peptide has reached a global licensing and collaboration agreement with Novartis for an undisclosed peptide asset in the field of radioligand therapy [2] Group 3 - The Hong Kong Stock Connect Innovative Drug Index aims to reflect the operational characteristics of listed companies in the innovative drug sector within the Hong Kong Stock Connect [3] - The top ten weighted stocks in the index include CSPC Pharmaceutical Group, BeiGene, CanSino Biologics, China National Pharmaceutical Group, Innovent Biologics, 3SBio, Hansoh Pharmaceutical, Kelun-Biotech, Kangzheng Pharmaceutical, and Ascentage Pharma-B [3]

Core Viewpoint - The Hong Kong Stock Connect Innovative Drug ETF (520880) experienced a strong increase, reaching a peak of 2.88% and currently up by 2.52% [1][4]. Group 1: ETF Performance - The ETF's price reached a high of 0.577, with a current price of 0.569, reflecting a gain of 0.014 or 2.52% [2][6]. - The trading volume for the ETF was reported at 178,084 shares, with a turnover rate of 3.73% [6]. Group 2: Component Stocks - Notable performers among the ETF's component stocks include China Biologic Products, BeiGene, and Hansoh Pharmaceutical, with respective increases of 5.21%, 3.53%, and 3.14% [1][5]. - Conversely, the stocks of Jiujiu Bio and Ascletis Pharma showed significant declines [1][5]. Group 3: Market Expectations - The JPM Healthcare Conference, held from January 12 to 15, 2026, has generated market anticipation regarding business development (BD) transaction data from Chinese innovative pharmaceutical companies, suggesting potential for increased international collaboration [6][7]. - The approval of updated labeling for the PD-1/VEGF dual antibody by the National Medical Products Administration for Kangfang Biopharma is expected to enhance treatment options for non-small cell lung cancer, indicating significant survival benefits [6][7]. Group 4: Industry Outlook - According to Western Securities, the innovative drug sector in Hong Kong is expected to maintain a structural market trend in 2026, with accelerated BD activities narrowing the price gap between Chinese and U.S. innovative drugs, leading to substantial long-term growth potential [7]. - Huafu Securities emphasizes that innovation will be a clear focus in 2026, particularly in cutting-edge technology platforms such as gene therapy and small nucleic acids [7].

Group 1 - Anta Sports (82020), Lenovo Group (80992), and Kuaishou (81024) have the highest short-selling ratios at 100.00%, 78.04%, and 71.83% respectively [1][2] - Alibaba (09988), Tencent Holdings (00700), and Xiaomi Group (01810) lead in short-selling amounts, with 2.968 billion, 1.700 billion, and 1.588 billion respectively [1][2] - China National Building Material (03323), Jiangsu Nanjing Highway (00177), and China Liansu (02128) have the highest deviation values at 33.68%, 31.58%, and 22.77% respectively [1][2] Group 2 - The top short-selling stocks by amount include Alibaba (09988) at 2.968 billion, Tencent Holdings (00700) at 1.700 billion, and Xiaomi Group (01810) at 1.588 billion [2] - The top short-selling ratios are led by Anta Sports (82020) at 100.00%, followed by Lenovo Group (80992) at 78.04%, and Kuaishou (81024) at 71.83% [2] - The highest deviation values are recorded for China National Building Material (03323) at 33.68%, Jiangsu Nanjing Highway (00177) at 31.58%, and China Liansu (02128) at 22.77% [2][3]

Core Viewpoint - The southbound capital flow into the Hong Kong stock market reached a record net inflow of 1,404.844 billion HKD in 2025, continuing into 2026 with a cumulative net inflow of 41.296 billion HKD as of January 13, 2026, indicating strong market performance driven by this influx [1][2]. Group 1: Southbound Capital Flow - In 2025, southbound capital became the largest source of incremental funds for the Hong Kong stock market, with a total net inflow of 1,404.844 billion HKD, setting a record for annual net inflow [2]. - As of January 13, 2026, there were 6 out of 7 trading days with net inflows, totaling 41.296 billion HKD since the beginning of the year [2]. - The number of shares held by southbound capital increased to 5,643.75 billion shares, with a market value of 6.33 trillion HKD, reflecting a growth of 0.19 trillion HKD since the start of 2026 [2]. Group 2: Market Performance - The Hang Seng Index rose over 4% and the Hang Seng Technology Index increased over 6% since the beginning of 2026, with more than 60% of stocks in the index with a market capitalization exceeding 1 trillion HKD showing an average increase of over 3% [1][5]. - The healthcare, materials, and conglomerates sectors led the market with increases of 15.46%, 12.86%, and 7.62% respectively, while only the telecommunications sector saw a decline of 0.49% [5][6]. - Major stocks such as Tencent Holdings and Alibaba-W saw significant increases, with Tencent rising 4.76% and Alibaba increasing 11.97% since the start of 2026 [6]. Group 3: Investment Outlook - Analysts predict that the southbound capital flow will continue to increase, driven by the low allocation of mainland investors in Hong Kong stocks and the trend of retail funds flowing into the market through ETFs [4]. - The market is expected to benefit from the "14th Five-Year Plan" and the dual easing of fiscal and monetary policies from major economies, with a focus on technology innovation and consumption themes [7][8]. - Five long-term investment directions are suggested: technology sectors including AI, healthcare, resource sectors benefiting from inflation, essential consumer sectors, and industries benefiting from RMB appreciation [8].

Core Viewpoint - The company has received approval from the U.S. Food and Drug Administration (FDA) for its novel drug SYH2072, a potent aldosterone synthase inhibitor, to conduct clinical trials in the U.S. This product has also been approved by the National Medical Products Administration (NMPA) in China for clinical trials starting in December 2025 [1][1]. Group 1 - The product is a highly selective and potent aldosterone synthase inhibitor (ASI) that effectively lowers plasma aldosterone levels without affecting cortisol levels [1][1]. - The approved clinical indications for SYH2072 are uncontrolled hypertension and resistant hypertension [1][1]. - Preclinical studies have shown that the product selectively inhibits aldosterone synthase activity, significantly reducing plasma aldosterone levels in animal disease models and dose-dependently lowering blood pressure in hypertension models, while not affecting cortisol levels [1][1]. Group 2 - The product exhibits favorable pharmacokinetic (PK) characteristics and safety, positioning it as a potential best-in-class drug [1][1]. - The company has submitted multiple patent applications for this product both domestically and internationally [1][1]. - Given the broad clinical demand for aldosterone synthase inhibitors, the product holds significant clinical development value and is expected to provide new treatment options for patients with uncontrolled and resistant hypertension [1][1].

该产品是一种高选择性强效醛固酮合成酶抑制剂(ASI)，可有效降低血浆醛固酮水平，且不影响皮质醇 水平。本次获批的临床适应症为未控制高血压和难治性高血压。临床前研究显示，该产品可选择性抑制 醛固酮合成酶的活性，在动物疾病模型中显著降低血浆醛固酮水平，并剂量依赖性地降低高血压模型的 血压，同时不影响皮质醇水平。该产品具有良好的药代动力学(PK)特性和安全性，使其具备成为一款同 类最优(best-in-class)药物的潜力。目前，集团已在国内外提交了该产品的多项专利申请。 石药集团(01093)发布公告，集团开发的化药1类新药强效醛固酮合成酶抑制剂(SYH2072片)(该产品)已获 得美国食品药品监督管理局批准，可在美国开展临床试验。该产品亦已于2025年12月获得中华人民共和 国国家药品监督管理局批准在中国开展临床试验。 鉴于醛固酮合成酶抑制剂的临床需求广阔，该产品具有较高的临床开发价值，有望为未控制高血压和难 治性高血压患者提供新的治疗选择。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產 生或因倚賴該等內容而引致之任何損失承擔任何責任。 石 藥 集 團 有 限 公 司 （股份代號：1093） （於香港註冊成立之有限公司） 自願公告 強效醛固酮合成酶抑制劑（SYH2072片） 在美國獲臨床試驗批准 承董事會命 石藥集團有限公司 主席 蔡東晨 CSPC PHARMACEUTICAL GROUP LIMITED 石 藥 集 團 有 限 公 司（「 本 公 司 」， 連 同 其 附 屬 公 司 統 稱「 本 集 團 」）董 事 會（「 董 事 會 」）欣 然 宣 布，本集團開發的化藥1類新藥強效醛固酮合成酶抑制劑（ SYH2072片 ）（「該產品」）已獲得美 國食品藥品監督管理局批准，可在美國開展臨床試驗。該產品亦已於2025年12月獲得中華 人民共和國國家藥品監督管理局批准在中國開展臨床試驗。 該產品是一種高選擇性強效醛固酮合成酶抑制劑(ASI)，可有效降低血漿醛固酮水平，且不 影響皮質醇水平。本次獲批的臨床適應症為未控制高血壓和難治性高血壓 ...

Core Viewpoint - The news highlights the strong performance of WuXi AppTec, with significant revenue and profit growth projections for 2025, driven by its integrated CRDMO business model and increasing demand for its services [3][4]. Group 1: Company Performance - WuXi AppTec expects to achieve approximately 454.56 billion yuan in revenue for 2025, representing a year-on-year growth of about 15.84%, with a 21.4% increase in revenue from continuing operations [3]. - The adjusted net profit attributable to shareholders is projected to be around 149.57 billion yuan, reflecting a year-on-year increase of approximately 41.33% [3]. - The company has revised its revenue guidance upwards, with total revenue expectations adjusted from 425-435 billion yuan to 435-440 billion yuan for 2025 [3]. Group 2: Market Trends - The Hang Seng Biotechnology ETF (513280) saw a 1.57% increase, with trading volume exceeding 1.4 billion yuan, indicating a significant uptick in market interest [1]. - WuXi AppTec's stock rose over 8%, outperforming many peers in the biotechnology sector, which also saw positive movements [4]. Group 3: Industry Insights - The AI healthcare application sector is rapidly advancing, with significant policy support and market demand driving commercialization [6]. - AI in drug development is expected to enhance early-stage research efficiency, significantly reducing the time required for drug candidate identification [6][7]. - The integration of AI in healthcare is becoming increasingly prevalent, with tools like ChatGPT Health facilitating better health information management for users [8][9].

Core Viewpoint - The news highlights the strong performance of WuXi AppTec, with significant revenue and profit growth projections for 2025, driven by its integrated CRDMO business model and increasing demand for its services [1][2]. Group 1: Company Performance - WuXi AppTec expects to achieve approximately CNY 45.456 billion in revenue for 2025, representing a year-on-year growth of about 15.84% [1]. - The company anticipates a substantial increase in adjusted net profit, projected at around CNY 14.957 billion, which is a year-on-year growth of approximately 41.33% [1]. - The revenue from continuing operations is expected to grow by about 21.4% year-on-year [1]. Group 2: Market Trends - The Hang Seng Biotechnology ETF (513280) saw a rise of 1.57%, with a trading volume exceeding CNY 1.4 billion, indicating increased investor interest in biotechnology stocks [1][3]. - WuXi AppTec's stock rose over 8%, reflecting positive market sentiment towards the company and its peers [3][4]. Group 3: Industry Insights - The company is focusing on its unique "integrated, end-to-end" CRDMO business model, which is expected to drive steady growth by meeting customer demands for enhanced capabilities [2]. - The demand for AI applications in healthcare is rapidly increasing, with significant policy support and technological advancements driving the sector's growth [5][6][7].

药明康德涨7.852%，药明生物涨5.588%，石药集团涨3.700%，阿里巴巴-W涨3.500%，翰森制药涨 3.494%， 中国人寿涨3.450%，恒基地产涨2.922%。 ...